FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2414103203> ?p ?o ?g. }

• W2414103203 endingPage "6328" @default.
• W2414103203 startingPage "6313" @default.
• W2414103203 abstract "It is hypothesized that selective muscarinic M1 subtype activation could be a strategy to provide cognitive benefits to schizophrenia and Alzheimer's disease patients while minimizing the cholinergic side effects observed with nonselective muscarinic orthosteric agonists. Selective activation of M1 with a positive allosteric modulator (PAM) has emerged as a new approach to achieve selective M1 activation. This manuscript describes the development of a series of M1-selective pyridone and pyridine amides and their key pharmacophores. Compound 38 (PF-06767832) is a high quality M1 selective PAM that has well-aligned physicochemical properties, good brain penetration and pharmacokinetic properties. Extensive safety profiling suggested that despite being devoid of mAChR M2/M3 subtype activity, compound 38 still carries gastrointestinal and cardiovascular side effects. These data provide strong evidence that M1 activation contributes to the cholinergic liabilities that were previously attributed to activation of the M2 and M3 receptors." @default.
• W2414103203 created "2016-06-24" @default.
• W2414103203 creator A5003784137 @default.
• W2414103203 creator A5004362084 @default.
• W2414103203 creator A5012463622 @default.
• W2414103203 creator A5012720499 @default.
• W2414103203 creator A5013579666 @default.
• W2414103203 creator A5016897967 @default.
• W2414103203 creator A5018630221 @default.
• W2414103203 creator A5019867231 @default.
• W2414103203 creator A5023424667 @default.
• W2414103203 creator A5030343494 @default.
• W2414103203 creator A5031121778 @default.
• W2414103203 creator A5034013182 @default.
• W2414103203 creator A5034802420 @default.
• W2414103203 creator A5036809859 @default.
• W2414103203 creator A5038573119 @default.
• W2414103203 creator A5039531502 @default.
• W2414103203 creator A5055125769 @default.
• W2414103203 creator A5058385063 @default.
• W2414103203 creator A5061415815 @default.
• W2414103203 creator A5070099912 @default.
• W2414103203 creator A5071684893 @default.
• W2414103203 creator A5071798264 @default.
• W2414103203 creator A5073672446 @default.
• W2414103203 creator A5073887610 @default.
• W2414103203 creator A5078493382 @default.
• W2414103203 creator A5088515526 @default.
• W2414103203 creator A5090701159 @default.
• W2414103203 date "2016-07-01" @default.
• W2414103203 modified "2023-10-16" @default.
• W2414103203 title "Discovery of the Potent and Selective M1 PAM-Agonist <i>N</i>-[(3<i>R</i>,4<i>S</i>)-3-Hydroxytetrahydro-2<i>H</i>-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects" @default.
• W2414103203 cites W1483229114 @default.
• W2414103203 cites W1964855841 @default.
• W2414103203 cites W1980949915 @default.
• W2414103203 cites W1988046782 @default.
• W2414103203 cites W1988137261 @default.
• W2414103203 cites W1988896100 @default.
• W2414103203 cites W1989379093 @default.
• W2414103203 cites W1990520277 @default.
• W2414103203 cites W2000127491 @default.
• W2414103203 cites W2001680184 @default.
• W2414103203 cites W2002178715 @default.
• W2414103203 cites W2004047252 @default.
• W2414103203 cites W2012286072 @default.
• W2414103203 cites W2016575780 @default.
• W2414103203 cites W2019130506 @default.
• W2414103203 cites W2019686582 @default.
• W2414103203 cites W2021390454 @default.
• W2414103203 cites W2026965429 @default.
• W2414103203 cites W2035695460 @default.
• W2414103203 cites W2040066247 @default.
• W2414103203 cites W2041517295 @default.
• W2414103203 cites W2047507052 @default.
• W2414103203 cites W2048123621 @default.
• W2414103203 cites W2050067210 @default.
• W2414103203 cites W2050512659 @default.
• W2414103203 cites W2051994079 @default.
• W2414103203 cites W2065133707 @default.
• W2414103203 cites W2072532414 @default.
• W2414103203 cites W2073735498 @default.
• W2414103203 cites W2078447826 @default.
• W2414103203 cites W2086818286 @default.
• W2414103203 cites W2095338436 @default.
• W2414103203 cites W2096345281 @default.
• W2414103203 cites W2108982217 @default.
• W2414103203 cites W2110569861 @default.
• W2414103203 cites W2112812864 @default.
• W2414103203 cites W2113544683 @default.
• W2414103203 cites W2118770079 @default.
• W2414103203 cites W2123500323 @default.
• W2414103203 cites W2147895703 @default.
• W2414103203 cites W2149860378 @default.
• W2414103203 cites W2150063046 @default.
• W2414103203 cites W2150232387 @default.
• W2414103203 cites W2174927484 @default.
• W2414103203 cites W2191453220 @default.
• W2414103203 cites W2220052208 @default.
• W2414103203 cites W2221959480 @default.
• W2414103203 cites W2278823400 @default.
• W2414103203 cites W2280892830 @default.
• W2414103203 cites W2312728139 @default.
• W2414103203 cites W2329765550 @default.
• W2414103203 cites W2409400995 @default.
• W2414103203 cites W2784414491 @default.
• W2414103203 cites W4230962467 @default.
• W2414103203 cites W2328958876 @default.
• W2414103203 doi "https://doi.org/10.1021/acs.jmedchem.6b00544" @default.
• W2414103203 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27275946" @default.
• W2414103203 hasPublicationYear "2016" @default.
• W2414103203 type Work @default.
• W2414103203 sameAs 2414103203 @default.
• W2414103203 citedByCount "71" @default.
• W2414103203 countsByYear W24141032032016 @default.
• W2414103203 countsByYear W24141032032017 @default.
• W2414103203 countsByYear W24141032032018 @default.
• W2414103203 countsByYear W24141032032019 @default.
• W2414103203 countsByYear W24141032032020 @default.

• next